Browsing by Author "Wong, V.W."

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • No Thumbnail Available
    Item
    A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease
    (Springer, 2024) Zhang, H.; Targher, G.; Byrne, C.D.; Kim, S.U.; Wong, V.W.; Valenti, L.; Glickman, M.; Ponce, J.; Mantzoros, C.S.; Crespo, J.; Gronbaek, H.; Yang, W.; Eslam, M.; Wong, R.J.; Machado, M.V.; Yu, M.; Ghanem, O.M.; Okanoue, T.; Liu, J.; Lee, Y.; Xu, X.; Pan, Q.; Sui, M.; Lonardo, A.; Yilmaz, Y.; Zhu, L.; Moreno, C.; Miele, L.; Lupsor-Platon, M.; Zhao, L.; LaMasters, T.L.; Gish, R.G.; Zhang, H.; Nedelcu, M.; Chan, W.K.; Xia, M.; Bril, F.; Shi, J.; Datz, C.; Romeo, S.; Sun, J.; Liu, D.; Sookoian, S.; Mao, Y.; Méndez-Sánchez, N.; Wang, X.; Pyrsopoulos, N.T.; Fan, J.; Fouad, Y.; Sun, D.; Giannini, C.; Chai, J.; Xia, Z.; Jun, D.W.; Li, G.; Treeprasertsuk, S.; Li, Y.; Cheung, T.T.; Zhang, F.; Goh, G.B.; Furuhashi, M.; Seto, W.; Huang, H.; Sessa, A.D.; Li, Q.; Cholongitas, E.; Zhang, L.; Silveira, T.R.; Sebastiani, G.; Adams, L.A.; Chen, W.; Qi, X.; Rankovic, I.; Ledinghen, V.D.; Lv, W.; Hamaguchi, M.; Kassir, R.; Müller-Wieland, D.; Romero-Gomez, M.; Xu, Y.; Xu, Y.; Chen, S.; Kermansaravi, M.; Kuchay, M.S.; Lefere, S.; Parmar, C.; Lip, G.Y.H.; Liu, C.; Åberg, F.; Lau, G.; George, J.; Sarin, S.K.; Zhou, J.; Zheng, M.; Niriella, M.A. (MAFLD ICD-11 coding collaborators)
    BACKGROUND With the implementation of the 11th edition of the International Classification of Diseases (ICD-11) and the publication of the metabolic dysfunction-associated fatty liver disease (MAFLD) nomenclature in 2020, it is important to establish consensus for the coding of MAFLD in ICD-11. This will inform subsequent revisions of ICD-11.METHODS Using the Qualtrics XM and WJX platforms, questionnaires were sent online to MAFLD-ICD-11 coding collaborators, authors of papers, and relevant association members.RESULTS A total of 890 international experts in various fields from 61 countries responded to the survey. We also achieved full coverage of provincial-level administrative regions in China. 77.1% of respondents agreed that MAFLD should be represented in ICD-11 by updating NAFLD, with no significant regional differences (77.3% in Asia and 76.6% in non-Asia, p = 0.819). Over 80% of respondents agreed or somewhat agreed with the need to assign specific codes for progressive stages of MAFLD (i.e. steatohepatitis) (92.2%), MAFLD combined with comorbidities (84.1%), or MAFLD subtypes (i.e., lean, overweight/obese, and diabetic) (86.1%).CONCLUSIONS This global survey by a collaborative panel of clinical, coding, health management and policy experts, indicates agreement that MAFLD should be coded in ICD-11. The data serves as a foundation for corresponding adjustments in the ICD-11 revision.